Literature DB >> 25506297

In-vitro Antiproliferative Activity of New Tetrahydroisoquinolines (THIQs) on Ishikawa Cells and their 3D Pharmacophore Models.

Suresh Kumar V K Eyunni1, Madhavi Gangapuram1, Kinfe K Redda1.   

Abstract

The antiproliferative activities of new substituted tetrahydroisoquinolines (THIQs) are described. Their cytotoxicities against Ishikawa human endometrial cell line were determined after 72 h drug expose employing Celtiter-Glo assay at concentrations ranging from 0.01 to 100,000 nM. The antiproliferative activities of the compounds understudy were compared to tamoxifen (TAM). In-vitro results indicated that most of the compounds showed better activity than TAM. The most active compounds obtained in this study were 1, 2, 3 and 22 whose IC50 values are 1.41, 0.91, 0.74 and 0.36 μM respectively. This study helped us to evaluate the risk of developing endometrial cancer in the design of non-steroid estrogen receptor modulators with no agonistic effects on uterus. In-silico pharmacophore hypotheses were generated using GALAHAD and PHASE and the best models with a probable bioactive conformation(s) for these compounds were proposed. These conformations and the alignments of the molecular structures give us an insight in designing compounds with better biological activity.

Entities:  

Keywords:  Antiproliferative agents; Ishikawa Cell lines; Pharmacophore Models; Tetrahydroisoquinolines

Year:  2014        PMID: 25506297      PMCID: PMC4264606          DOI: 10.2174/1570180811666131203002502

Source DB:  PubMed          Journal:  Lett Drug Des Discov        ISSN: 1570-1808            Impact factor:   1.150


  21 in total

1.  Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.

Authors:  Johanne Renaud; Serge François Bischoff; Thomas Buhl; Philipp Floersheim; Brigitte Fournier; Christine Halleux; Joerg Kallen; Hansjoerg Keller; Jean-Marc Schlaeppi; Wilhelm Stark
Journal:  J Med Chem       Date:  2003-07-03       Impact factor: 7.446

2.  Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists.

Authors:  Richard Chesworth; Michael P Zawistoski; Bruce A Lefker; Kimberly O Cameron; Robert F Day; F Michael Mangano; Robert L Rosati; Stacy Colella; Donna N Petersen; Amy Brault; Bihong Lu; Lydia C Pan; Pia Perry; Oicheng Ng; Tessa A Castleberry; Thomas A Owen; Thomas A Brown; David D Thompson; Paul DaSilva-Jardine
Journal:  Bioorg Med Chem Lett       Date:  2004-06-07       Impact factor: 2.823

3.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results.

Authors:  Steven L Dixon; Alexander M Smondyrev; Eric H Knoll; Shashidhar N Rao; David E Shaw; Richard A Friesner
Journal:  J Comput Aided Mol Des       Date:  2006-11-24       Impact factor: 3.686

4.  Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.

Authors:  G G Kuiper; B Carlsson; K Grandien; E Enmark; J Häggblad; S Nilsson; J A Gustafsson
Journal:  Endocrinology       Date:  1997-03       Impact factor: 4.736

5.  Synthesis and biological activity of 3-N-substituted estrogen derivatives as breast cancer agents.

Authors:  Zhongliang Wan; Musiliyu A Musa; Patrick Joseph; John S Cooperwood
Journal:  Mini Rev Med Chem       Date:  2013-07       Impact factor: 3.862

6.  Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

Authors:  E Erba; D Bergamaschi; L Bassano; G Damia; S Ronzoni; G T Faircloth; M D'Incalci
Journal:  Eur J Cancer       Date:  2001-01       Impact factor: 9.162

7.  Safety of prophylactic tamoxifen.

Authors:  D H Phillips; S Venitt
Journal:  Lancet       Date:  1993-06-05       Impact factor: 79.321

Review 8.  The strategic use of antiestrogens to control the development and growth of breast cancer.

Authors:  V C Jordan
Journal:  Cancer       Date:  1992-08-15       Impact factor: 6.860

Review 9.  Tamoxifen: a most unlikely pioneering medicine.

Authors:  V Craig Jordan
Journal:  Nat Rev Drug Discov       Date:  2003-03       Impact factor: 84.694

10.  Relationships among uterine growth, ornithine decarboxylase activity and polyamine levels: studies with estradiol and antiestrogens.

Authors:  E A Rorke; K L Kendra; B S Katzenellenbogen
Journal:  Mol Cell Endocrinol       Date:  1984-11       Impact factor: 4.102

View more
  4 in total

1.  Substituted Tetrahydroisoquinolines as Microtubule-destabilizing Agents in Triple Negative Human Breast Cancer Cells.

Authors:  Madhavi Gangapuram; Riccardo Jean; Elizabeth Mazzio; Ramesh Badisa; Suresh Eyunni; Carl B Goodman; Kinfe K Redda; Karam F Soliman
Journal:  Anticancer Res       Date:  2016-10       Impact factor: 2.480

2.  Synthesis and Pharmacological Evolution of Tetrahydroisoquinolines as Anti Breast Cancer Agents.

Authors:  Madhavi Gangapuram; Suresh Eyunni; Kinfe K Redda
Journal:  J Cancer Sci Ther       Date:  2014-04-25

3.  Discovery of Potential Orthosteric and Allosteric Antagonists of P2Y1R from Chinese Herbs by Molecular Simulation Methods.

Authors:  Xu Zhang; Fang Lu; Yan-Kun Chen; Gang-Gang Luo; Lu-di Jiang; Lian-Sheng Qiao; Yan-Ling Zhang; Yu-Hong Xiang
Journal:  Evid Based Complement Alternat Med       Date:  2016-08-21       Impact factor: 2.629

4.  Synthesis and Biological Evaluations of Ring Substituted Tetrahydroisoquinolines (THIQs) as Anti-Breast Cancer Agents.

Authors:  Suresh Vk Eyunni; Madhavi Gangapuram; Bereket Mochona; Nelly Mateeva; Kinfe K Redda
Journal:  J Cancer Sci Ther       Date:  2017-07-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.